Transcode Therapeutics, Inc. RNAZ
We take great care to ensure that the data presented and summarized in this overview for Transcode Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RNAZ
View allLatest Institutional Activity in RNAZ
Top Purchases
Top Sells
About RNAZ
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNA?based agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9?based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Insider Transactions at RNAZ
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 28
2023
|
Robert Michael Dudley Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
98,000
+35.22%
|
$0
$0.51 P/Share
|
|
Sep 28
2023
|
Thomas A Fitzgerald Interim CEO, CFO |
BUY
Open market or private purchase
|
Direct |
49,350
+46.7%
|
$0
$0.51 P/Share
|
|
Jun 21
2023
|
Robert Michael Dudley Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
12,000
+12.73%
|
$24,000
$2.65 P/Share
|
|
Jun 20
2023
|
Robert Michael Dudley Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
6,607
+8.6%
|
$13,214
$2.55 P/Share
|
|
Jun 09
2023
|
Robert Michael Dudley Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
19,000
+2.04%
|
$38,000
$2.76 P/Share
|
|
Sep 14
2022
|
Robert Michael Dudley Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+2.19%
|
$20,000
$1.15 P/Share
|
|
Jun 16
2022
|
Thomas A Fitzgerald Interim CEO, CFO |
BUY
Open market or private purchase
|
Direct |
12,000
+7.93%
|
$12,000
$1.27 P/Share
|
|
May 31
2022
|
Robert Michael Dudley Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+0.23%
|
$2,000
$1.87 P/Share
|
|
May 27
2022
|
Robert Michael Dudley Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
28,000
+3.11%
|
$28,000
$1.84 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 147K shares |
|---|